The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Osteopontin (OPN), TIMP-1, and interleukin (IL)-6 as prognostic (prog) for overall survival (OS) and independent from clinical criteria in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amado J. Zurita
No relevant relationships to disclose
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Anthony D'Amelio
Employment or Leadership Position - GlaxoSmithKline
Hai T. Tran
No relevant relationships to disclose
Arundathy N. Bartlett-Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
John Heymach
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline